ABSTRACT
Objective To investigate the clinical effects of prostaglandin E1 (PGE1) in the treatment ot chronic renal failure in the 2nd ～ 4th period.Methods 128 patients with CKDs at stage 2 to 4 were selected and randomly divided into the observation group and control group,64 cases in each group.Patients in control group were given routine drug treatment,and patients in observation group were given PGE1 on the basis of the control group.They all treated for 3 months.Renal function indicators before and after treatment,curative effect and adverse reaction were compared.Results There were no statistical differences in renal function indicators before treatment in two groups (t =0.27 ～ 0.95,P ＞ 0.05).After treatment,the 24 hours urinary protein (t =3.41,P ＜ 0.05),creatinine clearance rate (t =4.04,P ＜ 0.05),serum creatinine (t =4.15,P ＜ 0.05),serum urea nitrogen (t =3.92,P ＜ 0.05) between the two groups had statistical differences.Total effective rate of the observation group was 84.37％,which was significantly higher than 57.81％ of the control group (x2 =5.63,P ＜ 0.05).There was no adverse reaction observed in observation group.Conclusion PGE1 might improve patients' proteinuria and renal function in the current situation of lacking effective treatment.
ABSTRACT
Objective To investigate the mechanism of liposome PGE1 on the survival of the expanded flap.Methods The minipigs were set up as an animal model.They were divided into 2 groups.The expanded flaps (8 cm ×2 cm) were designed and elevated on the back of an minipig.An image analysis technology was used to evaluate the survival rate of the expanded flap,while realtimePCR technique was used to investigate the molecular mechanism.Results The survival area of the expanded flap in the Lipo PGE1 group was significantly enlarged (P＜0.01) compared with the control group.The VEGF,iNOS and Ang-1 gene expression decreased,but TGF-β1 gene expression increased.But there was no significant difference between two groups (P＞0.05).Conclusions The Lipo PGE1 could promote survival rate of the expanded flap,but the mechanism does not involve the regulation of VEGF,iNOS,Ang-1 and TGF-β1 gene expression.